Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Mesoblast share price rockets 30% on big US FDA news
Healthcare Shares
If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!
Share Fallers
Why 29Metals, Guzman Y Gomez, Mesoblast, and Pilbara Minerals shares are falling today
Healthcare Shares
What on Earth is happening with Mesoblast shares today?
ETFs
Vanguard Australian Shares Index ETF has lifted 20% in a year. Which stocks have contributed most to its rise?
Best Shares
Top ASX shares to buy in December 2024
Share Gainers
11 ASX All Ords shares rising faster than Nvidia over the past year
Best Shares
3 ASX 300 stocks up by more than 300% in a year
Healthcare Shares
Up 427% this year, why today is a big day for Mesoblast shares
Healthcare Shares
3 ASX healthcare shares going gangbusters on Thursday
Share Gainers
Why Block, Cettire, Mesoblast, and Regis Resources shares are rising today
Share Fallers
Why Karoon Energy, Mesoblast, Mineral Resources, and Sigma shares are falling today
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
